Evidence map›Paper›PMID 34741815›Full record

Trial reportLancet (London, England)2021

Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study.

Supriya G Mohile, Mostafa R Mohamed, Huiwen Xu, Eva Culakova, Kah Poh Loh, Allison Magnuson, Marie A Flannery, Spencer Obrecht, Nikesha Gilmore, Erika Ramsdale and 12 more

3 registry-linked trialsOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 274 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
274citing papers in PubMed, 11 pooled it
47.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02054741 nacompletednot on this map

A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults

TypeinterventionalSponsorSupriya MohileRan2014 to 2021Enrolled733ConditionsAdult Solid Neoplasm, Toxicity, LymphomaArmsComprehensive Geriatric Assessment, Quality-of-Life Assessment, Survey Administration
NCT06870617 recruitingnot on this mapstarted 2025, after this paper: background citation

Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations for Older Adults With Cancer (PACE-70): A Hybrid Implementation-effectiveness Study

TypeobservationalSponsorAbramson Cancer Center at Penn MedicineRan2025 to 2026Enrolled150ConditionsGeriatric Assessment, Advanced Cancer, ToxicityArmsPractical Geriatric Assessment, Correlation of body composition PGA and step count with outcomes
NCT07084454 phase3enrolling by invitationnot on this mapstarted 2024, after this paper: background citation

Geriatric Oncology Care in Brazil: Remote Geriatric Assessment-Driven Interventions With Supportive Care (The GAIN-S Trial in Brazil)

TypeinterventionalSponsorCristiane Decat Bergerot, PhDRan2024 to 2028Enrolled350ConditionsGeriatric Assessment, Geriatric Oncology, Quality of Life, Functional DeclineArmsGAIN-S Multidisciplinary Telehealth Intervention, Standard Oncology Care
3 · Its place in the literature

Who cites it

274 citing papers in PubMed, 11 syntheses or guidelines pooled it, 528 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Predictive value of the Cancer and Aging Research Group Score for chemotherapy toxicities in older adults with cancer: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Associations of frailty with symptoms, and HRQOL in older cancer survivors after cancer treatments: a systematic review and meta-analyses.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Pooled it
  8. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Guideline
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

214 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 1 country.

Supriya G MohileDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA; Department of Surgery, University of Rochester Cancer Center National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Research Base, Rochester, NY, USA. Electronic address: supriya_mohile@urmc.rochester.edu.
Mostafa R MohamedDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Huiwen XuDepartment of Surgery, University of Rochester Cancer Center National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Research Base, Rochester, NY, USA.
Eva CulakovaDepartment of Surgery, University of Rochester Cancer Center National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Research Base, Rochester, NY, USA.
Kah Poh LohDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Allison MagnusonDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Marie A FlanneryDepartment of Surgery, University of Rochester Cancer Center National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Research Base, Rochester, NY, USA.
Spencer ObrechtDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Nikesha GilmoreDepartment of Surgery, University of Rochester Cancer Center National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Research Base, Rochester, NY, USA.
Erika RamsdaleDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Richard F DunneDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Tanya WildesDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Sandy PlumbDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Amita PatilDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Megan WellsDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Lisa LowensteinDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michelle JanelsinsDepartment of Surgery, University of Rochester Cancer Center National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Research Base, Rochester, NY, USA.
Karen MustianDepartment of Surgery, University of Rochester Cancer Center National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Research Base, Rochester, NY, USA.
Judith O HopkinsSoutheast Clinical Oncology Research (SCOR) Consortium NCORP, Winston-Salem, NC, USA.
Jeffrey BerenbergHawaii Minority Underserved NCORP, Honolulu, HI, USA.
Navin AnthonySoutheast Clinical Oncology Research (SCOR) Consortium NCORP, Winston-Salem, NC, USA.
William DaleDepartment of Supportive Care, City of Hope National Medical Center, Duarte, CA, USA.
University of Rochester Medical Center · USUniversity of Rochester · USNational Cancer Institute · USSoutheast Clinical Oncology Research Consortium · USCity Of Hope National Medical Center · USOffice of Minority Health · USThe University of Texas MD Anderson Cancer Center · US

Funding

URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
The Hawaii NCORPUG1CA189804 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Jared Acoba, Jeffrey Lee Berenberg · 2014 to 2026
$15.7M
Institutional Career Development CoreKL2TR001999 · NCATS · UNIVERSITY OF ROCHESTER · PI XIAO, JIN · 2016 to 2024
$5.2M
Geriatric Oncology Research Infrastructure to Improve Clinical CareR33AG059206 · NIA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WILLIAM DALE, Heidi Diana Klepin · 2020 to 2026
$5.1M
Understanding Treatment Tolerability in Older Patients with CancerU01CA233167 · NCI · UNIVERSITY OF ROCHESTER · PI MOHILE, SUPRIYA G. · 2018 to 2023
$3.5M
Reducing Chemotherapy Toxicity in Older AdultsR01CA177592 · NCI · UNIVERSITY OF ROCHESTER · PI MOHILE, SUPRIYA G. · 2013 to 2018
$3.0M
A Patient-Oriented Research Program in Geriatric OncologyK24AG056589 · NIA · UNIVERSITY OF ROCHESTER · PI Supriya G. Mohile · 2018 to 2026
$1.5M
Mentoring the Next Generation of Geriatric Oncology Researchers in Patient-Oriented Research to Improve the Care of Older Adults with CancerK24AG055693 · NIA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WILLIAM DALE · 2018 to 2026
$1.4M
Mitigating Cancer-Related Cognitive Dysfunction in Older Adults with Breast CancerK76AG064394 · NIA · UNIVERSITY OF ROCHESTER · PI MAGNUSON, ALLISON MARIAN · 2019 to 2023
$1.3M
A Novel Mobile Health Exercise Intervention for Older Patients with Myeloid NeoplasmsK99CA237744 · NCI · UNIVERSITY OF ROCHESTER · PI LOH, KAH POH · 2019 to 2020
$385k
NCATS NIH HHS KL2 TR001999NCI NIH HHS K99 CA237744NCI NIH HHS R01 CA177592NCI NIH HHS U01 CA233167NCI NIH HHS UG1 CA189804NCI NIH HHS UG1 CA189961NIA NIH HHS K24 AG055693NIA NIH HHS K24 AG056589NIA NIH HHS K76 AG064394NIA NIH HHS R33 AG059206
6 · The paper itself

Abstract

backgroundOlder adults with advanced cancer are at a high risk for treatment toxic effects. Geriatric assessment evaluates ageing-related domains and guides management. We examined whether a geriatric assessment intervention can reduce serious toxic effects in older patients with advanced cancer who are receiving high risk treatment (eg, chemotherapy).

methodsIn this cluster-randomised trial, we enrolled patients aged 70 years and older with incurable solid tumours or lymphoma and at least one impaired geriatric assessment domain who were starting a new treatment regimen. 40 community oncology practice clusters across the USA were randomly assigned (1:1) to the intervention (oncologists received a tailored geriatric assessment summary and management recommendations) or usual care (no geriatric assessment summary or management recommendations were provided to oncologists) by means of a computer-generated randomisation table. The primary outcome was the proportion of patients who had any grade 3-5 toxic effect (based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4) over 3 months. Practice staff prospectively captured toxic effects. Masked oncology clinicians reviewed medical records to verify. The study was registered with ClinicalTrials.gov, NCT02054741.

findingsBetween July 29, 2014, and March 13, 2019, we enrolled 718 patients. Patients had a mean age of 77·2 years (SD 5·4) and 311 (43%) of 718 participants were female. The mean number of geriatric assessment domain impairments was 4·5 (SD 1·6) and was not significantly different between the study groups. More patients in intervention group compared with the usual care group were Black versus other races (40 [11%] of 349 patients vs 12 [3%] of 369 patients; p<0·0001) and had previous chemotherapy (104 [30%] of 349 patients vs 81 [22%] of 369 patients; p=0·016). A lower proportion of patients in the intervention group had grade 3-5 toxic effects (177 [51%] of 349 patients) compared with the usual care group (263 [71%] of 369 patients; relative risk [RR] 0·74 (95% CI 0·64-0·86; p=0·0001). Patients in the intervention group had fewer falls over 3 months (35 [12%] of 298 patients vs 68 [21%] of 329 patients; adjusted RR 0·58, 95% CI 0·40-0·84; p=0·0035) and had more medications discontinued (mean adjusted difference 0·14, 95% CI 0·03-0·25; p=0·015).

interpretationA geriatric assessment intervention for older patients with advanced cancer reduced serious toxic effects from cancer treatment. Geriatric assessment with management should be integrated into the clinical care of older patients with advanced cancer and ageing-related conditions.

fundingNational Cancer Institute.

Indexed as

Geriatric AssessmentAccidental FallsAgedAged, 80 and overAgingAntineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleNeoplasmsOncologistsAntineoplastic Agents

Identifiers

PMID34741815
PMCPMC8647163
OpenAlexW3209480926

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.